Sinovac Biotech Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sinovac Biotech Ltd (SVA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sinovac Biotech Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 386M vs 5M combined for its competitors (98.8% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-116.9%) for its tracked peer group.
- Peer revenue share: Sinovac Biotech Ltd accounted for 100.1% of combined revenue among its tracked peer group, up from 99.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.15M compares with $0.02M for the peer group (8.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SVA Sales vs. its Competitors, Q4 2025
Sinovac Biotech Ltd generated 100.05 % of the combined sales of its peer group, up from 99.79 % a year earlier.
API endpoints for this dataset
Sinovac Biotech Ltd vs. its Competitors, Q4 2025
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Sinovac Biotech Ltd reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sinovac Biotech Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sinovac Biotech Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sinovac Biotech Ltd's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 7.0% for Sinovac Biotech Ltd. Sinovac Biotech Ltd's share of combined industry revenue moved from 0.08% to 0.07%, a gain of 0.00 percentage points.
Sinovac Biotech Ltd's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sinovac Biotech Ltd | No | Yes | No | Yes |
| Competitors combined (3) | - | |||
| High-Confidence Competitors (1) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SVA Stock Performance relative to its Competitors
SVA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Aura Biosciences Inc | 282.9% | Outperformed |
| 2 | Titan Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Ocugen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sinovac Biotech Ltd's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Sinovac Biotech Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Sinovac Biotech Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Sinovac Biotech Ltd |
464.94 | 385.98 |
 Aura Biosciences Inc |
724.28 | - |
 Ocugen Inc |
342.07 | 4.58 |
 Titan Pharmaceuticals Inc |
4.91 | -0.28 |
| SUBTOTAL | 1,536.20 | 390.28 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sinovac Biotech Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sinovac Biotech Ltd's Competitors Named by the Company
Competitive relationships identified from Sinovac Biotech Ltd reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ocugen Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Sinovac Biotech Ltd's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Sinovac Biotech Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sinovac Biotech Ltd | 465 | 148,340 | -76,417 |
| Aura Biosciences Inc | 724 | - | -1,159,389 |
| Ocugen Inc | 342 | 39,483 | -705,267 |
| Titan Pharmaceuticals Inc | 5 | -71,000 | -701,250 |
| PEERS TOTAL | 1,071 | 18,438 | -925,438 |
Sinovac Biotech Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Sinovac Biotech Ltd | CN 82.34 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sinovac Biotech Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 492 companies in Sinovac Biotech Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Sinovac Biotech Ltd ranks #0 of 492 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 975, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 23.62 % |
| 2 | Johnson and Johnson | 688,377 | 12.89 % |
| 3 | Abbvie Inc | 519,434 | 9.73 % |
| 4 | Merck and Co Inc | 367,314 | 6.88 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Sinovac Biotech Ltd | 465 | 0.00 % |
Market cap and industry share for the rest of Sinovac Biotech Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-28.
Sinovac Biotech Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 67.87 % | 37.93 % (avg) | +29.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | -44.86 % | -6.39 % (avg) | -38.5 pp |
| Capital Intensity (Capex / Revenue) | 12.73 % | 7.56 % (avg) | +5.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sinovac Biotech Ltd's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.4x | - |
| EV / EBITDA | - | 15.3x | - |
| P/B | 0.1x | 4.2x | -4.1x |
| Return on Equity | -3.11 % | industry aggregate | -23.23 % |
| Return on Invested Capital | -3.12 % | -9.78 % (avg) | 6.66 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Sinovac Biotech Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -70.01 % | -19.45 % | 7.01 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -3.34 % | -2.49 % | -3.12 % |
| P/E | - | 5.1x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sinovac Biotech Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 975 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 12.73 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Sinovac Biotech Ltd's dedicated Suppliers and Customers pages, not here.
Sinovac Biotech Ltd's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Sinovac Biotech Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sinovac Biotech Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 23.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-116.9% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Sinovac Biotech Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sinovac Biotech Ltd | 0.75 | 4.59 | 0.08 |
| Aura Biosciences Inc | 3.53 | 10.44 | - |
| Ocugen Inc | 0.93 | 1.05 | - |
| Titan Pharmaceuticals Inc | 7.86 | 8.40 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sinovac Biotech Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sinovac Biotech Ltd | Q4 2025 | +7.0 % | - |
| Aura Biosciences Inc | Q2 2026 | - | - |
| Ocugen Inc | Q2 2026 | +8.4 % | - |
| Titan Pharmaceuticals Inc | Q2 2025 | - | - |
| PEERS TOTAL | +7.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sinovac Biotech Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sinovac Biotech Ltd | Q4 2025 | -11.9 % | +2,919.1 % |
| Aura Biosciences Inc | Q2 2026 | - | -46.2 % |
| Ocugen Inc | Q2 2026 | - | -51.2 % |
| Titan Pharmaceuticals Inc | Q2 2025 | - | - |
Sinovac Biotech Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sinovac Biotech Ltd | - | - | - |
| Aura Biosciences Inc | - | - | - |
| Ocugen Inc | - | - | - |
| Titan Pharmaceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sinovac Biotech Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sinovac Biotech Ltd | - | 1.20 |
| Aura Biosciences Inc | - | - |
| Ocugen Inc | - | 74.69 |
| Titan Pharmaceuticals Inc | - | - |
| PEERS AVERAGE | - | 3.94 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.